Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker used primarily for the management of hypertension. It acts by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels in vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance. This mechanism decreases systemic blood pressure and myocardial oxygen demand while increasing oxygen delivery to cardiac tissue. Nisoldipine is more potent as a vasodilator than nifedipine and can be used alone or in combination with other antihypertensive agents such as ACE inhibitors, diuretics, or beta-blockers. Off-label, it may be used for ischemic heart conditions like stable angina and Prinzmetal angina[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nisoldipine.